(Q42943536)

English

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

scientific article published on August 6, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

peginterferon alfa-2b

1 reference

based on heuristic

inferred from title

author name string

Jonathan McCone

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

David Pound

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Natarajan Ravendhran

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Lorenzo Rossaro

11

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Raymond Rubin

14

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Kenneth Koury

15

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Eirum Chaudhri

18

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

SPRINT-1 investigators

20

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Paul Y. Kwo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Eric J. Lawitz

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Eugene R. Schiff

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

John M. Vierling

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Mitchell N. Davis

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Joseph S. Galati

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Stuart C. Gordon

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Frank H. Anderson

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Ira M. Jacobson

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Lisa D. Pedicone

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Clifford A. Brass

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

Janice K. Albrecht

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

language of work or name

0 references

publication date

6 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

full work available at URL

https://iris.unipa.it/bitstream/10447/73859/1/Kwo.pdf

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692693

18 June 2024

https://api.elsevier.com/content/article/PII:S0140673610609348?httpAccept=text/xml

1 reference

10.1016/S0140-6736(10)60934-8

https://api.crossref.org/works/10.1016/S0140-6736(10)60934-8

18 June 2024

https://api.elsevier.com/content/article/PII:S0140673610609348?httpAccept=text/plain

1 reference

10.1016/S0140-6736(10)60934-8

https://api.crossref.org/works/10.1016/S0140-6736(10)60934-8

18 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

376

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

9742

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

705-716

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Hepatitis C virus and liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir, an NS3 protease inhibitor of HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of resistance mutations against HCV ketoamide protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960934-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)60934-8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42943536&oldid=2182880265"